Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 16-week, Randomized, Placebo-controlled, Double Blind, and Parallel Group Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease

NCT01509677 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01509677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01509677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 16-week, Randomized, Placebo-controlled, Double Blind, and Parallel Group Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
February 1, 2012
Completion date
February 1, 2016
Enrollment
158 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease, copd